Exploring targeted therapy in retinal vasculopathy with cerebral leukoencephalopathy: a case report and review of literature

Read full text
Authors: Patricia Tato-Moreno, Cristina Lavilla Olleros, Hector Balastegui Martin, M. Barrientos Guerrero, Anna Mensa-Vilaro, María Esther Durán-García, Paloma Sánchez‐Mateos, Elena García-Martínez
Cited by: 1
References: 21

Abstract

Retinal vasculopathy with cerebral leukoencephalopathy and systemic manifestations (RVCL-S) is a rare autosomal dominant microvascular disorder caused by C-terminal truncating mutations in TREX1 gene, which impair protein localization and lead to multisystem involvement. We report a patient carrying the pathogenic TREX1 variant NM_033629.6:c.703dup (p.Val235fs), the most frequently described mutation in RVCL-S, whose clinical course was consistent with the classic phenotype but with simultaneous pulmonary granulomatous lesions compatible with sarcoidosis. Transcriptomic analysis in both the patient and his pre-asymptomatic daughter, who carries the same variant, revealed a similarly mild upregulation of inflammatory signaling pathways. Treatment with a Janus kinase inhibitor in the patient was followed by transient clinical stabilization before subsequent progression. This case expands the phenotypic spectrum of RVCL-S and underscores the importance of systematic immunological monitoring and clinical surveillance to support future development of timely strategies in asymptomatic carriers.

Fields of Study & Subjects

interferon and immune responses Ocular Diseases and Behçet’s Syndrome RNA regulation and disease

Publication details

Journal / source
Frontiers in Immunology
Publisher
Frontiers Media SA
Volume
16
Pages
1707532–1707532
Publication date
14 January 2026
Language
EN